Multiple approaches are being developed to address the loss of sight in retinal degeneration (Scholl et al.,
2016), including gene therapy (Sengillo, Justus, Tsai, Cabral, & Tsang,
2016), cell transplantation (Lorach et al.,
2019; Seiler et al.,
2008), optogenetics (Barrett, Berlinguer-Palmini, & Degenaar,
2014), and electronic implants. In the latter case, an array of electrodes is placed at the stimulation site, such as the retina (D. Palanker & Goetz,
2018), optic nerve (Veraart, Wanet-Defalque, Gérard, Vanlierde, & Delbeke,
2003), lateral geniculate nucleus (LGN; Nguyen et al.,
2016), or primary visual cortex (Lewis, Ackland, Lowery, & Rosenfeld,
2015). Electric current is injected into tissue to stimulate cells and thereby elicit visual perception. Upon electrode activation, patients report perceiving “bright spots,” termed phosphenes (Humayun et al.,
2012; Stingl et al.,
2015). The number of electrodes limits the amount of information deliverable, and electrode density restricts the highest possible resolution. In animal studies with photovoltaic retinal prosthesis, we demonstrated that grating acuity matches the pixel pitch with 55 (Ho, Lorach, Huang, et al.,
2018) and 75 μm pixels (Lorach, Goetz, Smith, et al.,
2015). Recent clinical trial of such implants (PRIMA, by Pixium Vision) having 100μm pixels also demonstrated that prosthetic visual acuity in AMD patients is only 10%–30% below the sampling limit of 20/420 for the current pixel size (D. V. Palanker et al.,
2019).